Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Bladder Cancer

Clinical and regulatory intelligence for Bladder Cancer with 13 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
13
Catalysts
0
Assets
9

Relevant assets

Astellas →
enGene →
erdafitinib →
FDA →
Imfinzi →
KEYTRUDA →
MHRA →
pembrolizumab →
TYRA-300 →

Relevant companies

AstraZeneca →
Janssen Pharmaceutical K.K. →
Merck →
Pfizer →

Recent signals(13)

ClinicalJuly 31, 2026

Robotic-assisted surgery reduces complications in bladder cancer patients

The study shows that robotic-assisted intracorporeal radical cystectomy with modified ileal conduit significantly reduces the risk of ureteroileal anastomotic stenosis compared to traditional laparoscopic surgery.

ClinicalJuly 27, 2026

enGene Initiates LEGEND Study of EG-70 in BCG-Unresponsive NMIBC Patients

The LEGEND study will evaluate the safety and efficacy of EG-70 in patients with BCG-unresponsive NMIBC.

ClinicalJuly 18, 2026

BRIGHT Trial: Pembrolizumab and Radiation Therapy for Muscle Invasive Bladder Cancer

The BRIGHT trial is a phase II study evaluating pembrolizumab combined with radiation therapy post-chemotherapy to avoid bladder removal in muscle invasive bladder cancer patients.

RegulatoryJuly 11, 2026

FDA Approves Pembrolizumab Combinations for Muscle Invasive Bladder Cancer

The FDA has approved pembrolizumab alone or in combination with berahyaluronidase alfa-pmph and enfortumab vedotin-ejfv for muscle invasive bladder cancer.

RegulatoryJuly 11, 2026

FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment

The FDA has approved PADCEV in combination with Keytruda as a neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, regardless of cisplatin eligibility.

ClinicalJuly 7, 2026

Janssen initiates study on erdafitinib intravesical delivery for bladder cancer in Japan

A clinical trial is underway to assess the tolerability of an intravesical delivery system for erdafitinib in Japanese patients with bladder cancer.

RegulatoryJuly 2, 2026

MHRA Approves Gemcitabine Delivery System for High-Risk Bladder Cancer

The MHRA has authorized a new intravesical delivery system for gemcitabine aimed at adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer.

ClinicalJune 28, 2026

Phase 2 Study of TYRA-300 Shows Promise for FGFR3 Altered NMIBC

Tyra Biosciences is conducting Phase 2 study of TYRA-300 targeting FGFR3 alterations in low grade, intermediate risk non-muscle invasive bladder cancer.

RegulatoryJune 26, 2026

FDA Accepts Supplement for Cysview Kit by Photocure ASA

The FDA has accepted a supplemental application for the Cysview Kit, which contains hexaminolevulinate hydrochloride.

RegulatoryJune 25, 2026

European Commission Approves KEYTRUDA Plus Padcev for Cisplatin-Ineligible Bladder Cancer

The European Commission has approved KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

RegulatoryJune 17, 2026

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

The FDA has granted priority review for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for muscle-invasive bladder cancer.

ClinicalJune 16, 2026

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

The Phase III VOLGA trial demonstrated that perioperative Imfinzi plus neoadjuvant EV significantly improves event-free survival and shows a favorable trend in overall survival for muscle-invasive bladder cancer.

RegulatoryJune 16, 2026

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

The EU CHMP has issued a positive opinion for the combination of KEYTRUDA and Padcev as a treatment for cisplatin-ineligible muscle-invasive bladder cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Bladder Cancer →
Oncology →
Urology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.